Wednesday, February 26, 2020 10:23:24 AM
today announced progress in its efforts to develop a novel vaccine to protect against coronavirus disease COVID-19.
Novavax has produced and is currently assessing multiple nanoparticle vaccine candidates in animal models prior to identifying an optimal
candidate for human testing, which is expected to begin by the end of spring 2020.
Novavax created the COVID-19 vaccine candidates using its
proprietary recombinant protein nanoparticle technology platform to generate antigens derived from the coronavirus spike (S) protein.
Novavax expects to utilize its proprietary Matrix-M™ adjuvant with its COVID-19 vaccine candidate to enhance immune responses.
“Our previous experience working with other corona viruses,
including both MERS and SARS,
allowed us to mobilize quickly against COVID-19 and successfully complete the critical preliminary steps to engineer viable vaccine candidates,” said Stanley C. Erck, President and Chief Executive Officer of Novavax.
“Now that the protein has been expressed stably in our baculovirus system, we aim to identify the optimal candidate and scale up
production of sufficient vaccine for preliminary clinical trials.
We are now well-positioned to advance the COVID-19 vaccine candidate to Phase I clinical testing in May or June.”
Novavax has a proven track record of rapid innovative vaccine development against novel emerging viruses, including efforts to
develop vaccines against previous coronaviruses,
Middle East Respiratory Syndrome (MERS-CoV), and Severe Acute Respiratory Syndrome (SARS). In both cases,
Novavax’ candidate vaccines demonstrated strong immunogenicity and
100% protection against virus challenge in preclinical testing.
Novavax also developed a safe and clinically immogenetic Ebola vaccine candidate that proved effective in primate studies.
About Coronaviruses
A new strain of coronavirus first appeared in late 2019 in China
before beginning its rapid spread across the globe.
The disease, named COVID-19, continues to cause severe pneumonia-like symptoms in many of those infected. Coronaviruses,
so named for their “crown-like” appearance, are a large family of viruses that spread from animals to humans and include diseases such
as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) in addition to COVID-19.
While much remains unknown about the new coronavirus, it is known that the virus can spread via human-to-human transmission before any symptoms appear.
About Matrix-M™
Novavax’ patented saponin-based Matrix-M adjuvant has demonstrated
a potent and well-tolerated effect by stimulating the entry of antigen-
presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune responses.
About Novavax
Novavax, Inc. (Nasdaq:NVAX), is a late-stage biotechnology company
that drives improved health globally through the discovery, development,
and commercialization of innovative vaccines to prevent serious infectious diseases. NanoFlu™, its quadrivalent influenza nanoparticle vaccine,
is currently in a pivotal Phase 3 clinical trial to address key factors that can lead to the poor effectiveness of currently approved flu vaccines.
ResVax™, its RSV vaccine for infants via maternal immunization,
is the only vaccine in a Phase 3 clinical program and is designed to prevent severe lower respiratory tract infection,
which is the second leading cause of death in children under one year of age worldwide. Novavax is a leading innovator of recombinant vaccines;
its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Forward-Looking Statements
Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products, including those regarding the potential for NanoFlu to offer broadly protective immunity and improved vaccine efficacy, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2018, and Quarterly Report on Form 10-Q for the period ended September 30, 2019, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Contacts:
Investors
Novavax, Inc.
Erika Trahan
ir@novavax.com
240-268-2022
Westwicke
John Woolford
john.woolford@westwicke.com
443-213-0506
Media
Brandzone/KOGS Communication
Edna Kaplan
kaplan@kogspr.com
617-974-8659
Primary Logo
Recent NVAX News
- Shah Capital nominates two highly qualified independent director candidates for Novavax • GlobeNewswire Inc. • 04/15/2024 10:00:00 AM
- Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024 • PR Newswire (US) • 04/01/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 12:30:14 AM
- Novavax to Participate in TD Cowen's 44th Annual Health Care Conference • PR Newswire (US) • 02/29/2024 09:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 01:07:50 PM
- Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights • PR Newswire (US) • 02/28/2024 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 12:30:55 PM
- Goldman Sachs Reconsiders Fed Cuts, LUNR Surges Over 40% in Pre-Market, and More • IH Market News • 02/23/2024 01:03:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 11:02:36 AM
- Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement • PR Newswire (US) • 02/22/2024 11:00:00 AM
- Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024 • PR Newswire (US) • 02/20/2024 02:25:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 01:00:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 10:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 02:25:15 PM
- Novavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 01/03/2024 02:25:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2023 10:12:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2023 10:09:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2023 10:00:29 PM
- Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan • PR Newswire (US) • 12/18/2023 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 10:00:21 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 10:00:16 PM
- Moderna Shares, Other Covid Vaccine Makers Hit by Warning From Pfizer • Dow Jones News • 12/13/2023 01:31:00 PM
- Canadians Can Help Protect Loved Ones as We Head into the Holiday Season • PR Newswire (Canada) • 12/13/2023 01:00:00 PM
- Novavax's Updated COVID-19 Vaccine Now Authorized in Canada • PR Newswire (US) • 12/05/2023 09:01:00 PM
- Novavax's Updated COVID-19 Vaccine Now Authorized in Canada • PR Newswire (Canada) • 12/05/2023 09:01:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM